Loading
This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.
The registry lists NCT07756281 as not yet recruiting, last updated 2026-08-10. Enrolment is 40 planned participants, an estimate. Interventions: SNV1521, daraxonrasib. Primary measures include Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities. No results are posted in the registry; this does not exclude separate publications.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Shares PARP, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/